ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM),…
VivoPower Commences $29 Million Shareholder Loan Financing Retirement Plan
LONDON, July 07, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR)…
“AI and the Art Market” by Arte, with Artprice by Artmarket and analysis by Perplexity.AI Labs
PARIS, June 16, 2025 /PRNewswire/ -- This Sunday, June 15th, 2025, the…
